Tarsus Pharmaceuticals Inc.

06/22/2021 | Press release | Distributed by Public on 06/22/2021 14:42

Submission of Matters to a Vote of Security Holders (Form 8-K)

Submission of Matters to a Vote of Security Holders.

On June 15, 2021, Tarsus Pharmaceuticals, Inc. (the 'Company') held its Annual Meeting of Stockholders (the 'Annual Meeting'). The Company filed its definitive proxy statement for the proposals voted upon at the Annual Meeting with the Securities and Exchange Commission on April 30, 2021 (the 'Proxy Statement').

At the close of business on April 19, 2021, the record date of the Annual Meeting, the Company had 20,703,852 shares of common stock outstanding and entitled to vote. The holders of a total of 14,779,289 shares of common stock were present at the Annual Meeting, either in person or by proxy, which total constituted a quorum of the issued and outstanding shares on the record date of the Annual Meeting.

The following proposals were submitted to the Company's stockholders at the Annual Meeting:

1. The election of two Class I directors to serve until the Company's 2024 annual meeting of stockholders.

2. The ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021.

The number of votes cast for and against or withheld and the number of abstentions and broker non-voteswith respect to each matter voted upon, as applicable, are set forth below:

1. Board of Directors Election Results

The following nominees were elected to serve as Class I directors for a term that will continue until the 2024 annual meeting of stockholders or until their respective successors have been duly elected and qualified. The number of votes cast for and withheld and the number broker non-votesfor each nominee were as follows:

Director Name

Votes For Votes Withheld Broker Non-Votes

William J. Link, Ph.D.

10,943,583 393,838 3,441,868

Jason Tester

11,178,808 158,613 3,441,868

The following directors, in addition to Dr. Link and Mr. Tester, will continue to serve as members of our Board of Directors until the expiration of their respective terms or until their respective successors have been duly elected and qualified: Michael Ackermann, Ph.D., Bobak Azamian, M.D., Ph.D., Bhaskar Chaudhuri, Ph.D., Andrew Goldberg, M.D., and Wendy Yarno.

2. Ratification of Ernst & Young LLP as our independent registered public accounting firm

Our stockholders ratified the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021. The number of votes cast for and against and the number of abstentions for this proposal were as follows (there were no broker non-votesfor this proposal):

Votes For

Votes Against

Abstain

14,778,223 50 1,016